Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15,358 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity.
Regan JA, Cao Y, Dispenza MC, Ma S, Gordon LI, Petrich AM, Bochner BS. Regan JA, et al. Among authors: ma s. J Allergy Clin Immunol. 2017 Sep;140(3):875-879.e1. doi: 10.1016/j.jaci.2017.03.013. Epub 2017 Apr 4. J Allergy Clin Immunol. 2017. PMID: 28389390 Free PMC article. No abstract available.
Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes.
Frankfurt O, Ma S, Gordon L, Winter JN, Horowitz JM, Rademaker A, Weitner BB, Peterson LC, Altman JK, Tallman MS, Petrich A, Rosen ST. Frankfurt O, et al. Among authors: ma s. Leuk Lymphoma. 2015 Feb;56(2):315-23. doi: 10.3109/10428194.2014.910654. Epub 2014 Jun 17. Leuk Lymphoma. 2015. PMID: 24707943 Clinical Trial.
Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia.
Brown JR, Harb WA, Hill BT, Gabrilove J, Sharman JP, Schreeder MT, Barr PM, Foran JM, Miller TP, Burger JA, Kelly KR, Mahadevan D, Ma S, Li Y, Pierce DW, Barnett E, Marine J, Miranda M, Azaryan A, Yu X, Nava-Parada P, Mei J, Kipps TJ. Brown JR, et al. Among authors: ma s. Haematologica. 2016 Jul;101(7):e295-8. doi: 10.3324/haematol.2015.140806. Epub 2016 May 5. Haematologica. 2016. PMID: 27151992 Free PMC article. Clinical Trial. No abstract available.
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.
Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, Collins GP, Ma S, Coleman M, Peles S, Smith S, Barrientos JC, Smith A, Munneke B, Dimery I, Beaupre DM, Chen R. Noy A, et al. Among authors: ma s. Blood. 2017 Apr 20;129(16):2224-2232. doi: 10.1182/blood-2016-10-747345. Epub 2017 Feb 6. Blood. 2017. PMID: 28167659 Free PMC article. Clinical Trial.
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas.
Pearse WB, Petrich AM, Gordon LI, Karmali R, Winter JN, Ma S, Kaplan JB, Behdad A, Klein A, Jovanovic B, Helenowski I, Smith SM, Evens AM, Pro B. Pearse WB, et al. Among authors: ma s. Leuk Lymphoma. 2021 Dec;62(14):3493-3500. doi: 10.1080/10428194.2021.1957867. Epub 2021 Aug 2. Leuk Lymphoma. 2021. PMID: 34338127 Clinical Trial.
Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL.
Zurko J, Nizamuddin I, Epperla N, David K, Cohen JB, Moyo TK, Ollila T, Hess B, Roy I, Ferdman R, Liu J, Chowdhury SM, Romancik J, Bhansali RS, Harris EI, Sorrell M, Masel R, Kittai AS, Denlinger N, Sigmund AM, Fitzgerald L, Galvez C, Ma S, Winter J, Pro B, Gordon LI, Danilov A, Stephens D, Shah NN, Kenkre V, Barta SK, Torka P, Shouse G, Karmali R. Zurko J, et al. Among authors: ma s. Blood Adv. 2023 Jun 27;7(12):2657-2669. doi: 10.1182/bloodadvances.2022008240. Blood Adv. 2023. PMID: 36094847 Free PMC article.
15,358 results
You have reached the last available page of results. Please see the User Guide for more information.